Can Dysregulated Metabolic Features Predict Survival in Patients with AML?
Researchers identified dysregulated metabolic features in Acute Myeloid Leukemia (AML) to predict patient survival, according to an article published in the journal Frontiers in Oncology.
Prognostic metabolic genes were identified in the RNA matrix and clinical data of patients with AML included in the GEO, TCGA, and TARGET databases. Nine genes were identified in order to construct a prognostic model of shorter survival in a high-risk versus low-risk group.
Good predictive efficacy was shown in the prognostic model, with the metabolic signature demonstrating independent prognostic value.
When metabolic signatures and classic prognostic factors were combined, the 5-year overall survival prediction was improved compared to just classic prognostic factor predictions.
A gene set enrichment analyses showed that most pathways were metabolism-related.
Wang Y, Hu F, Li JY, et al. Systematic Construction and Validation of a Metabolic Risk Model for Prognostic Prediction in Acute Myelogenous Leukemia. Front Oncol. 2020;10:540.